Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8384-8390

  Psyrri, Amanda ^a,c   Bamias, Aris ^b   Yu, Ziwei ^a   Weinberger, Paul M ^a   Kassar, Mohamad ^a   Markakis, Sophia ^b   Kowalski, Diane ^a   Efstathiou, Eleni ^b   Camp, Robert L ^a   Rimm, David L ^a   Dimopoulos, Meletios A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR; PACLITAXEL; PLATINUM; PROTEIN P27;

ADULT; AGED; ARTICLE; AUTOMATION; CANCER STAGING; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DRUG TARGETING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SUBCELLULAR FRACTIONS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 28544433273     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1270     Document Type: Article

References (42)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC, Jr. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703-7.
3. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82: 1535-8.
4. Blain SW, Scher HI, Cordon-Cardo C, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003;3: 111-5.
5. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44.
6. Bullrich F, MacLachlan TK, Sang N, et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res 1995;55:1199-205.
7. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
8. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8: 1323-7.
9. WHO. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): WHO; 1979.
10. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7: 24-31.
11. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8.
12. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
13. Fernebro E, Dictor M, Bendahl PO, Ferno M, Nilbert M. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 2002;126:702-5.
14. Claudio PP, Zamparelli A, Garcia FU, et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002;8:1808-15.
15. Beumer TL, Kiyokawa H, Roepers-Gajadien HL, et al. Regulatory role of p27kip1 in the mouse and human testis. Endocrinology 1999;140:1834-40.
16. Ozkara SK, Corakci A. Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression). Pathol Oncol Res 2004;10:89-97.
17. Reilly JF, Martinez SD, Mickey G, Maher PA. A novel role for farnesyl pyrophosphate synthase in fibroblast growth factor-mediated signal transduction. Biochem J 2002;366:501-10.
18. Yuan JQ, Xu JY, Zhang J, He QC, Zhu J, Sheng CX. Expression and significance of cyclin D1, p27kip1 protein in bronchioloalveolar carcinoma. J Zhejiang Univ Sci 2004;5:235-41.
19. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" outpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86: 829-35.
20. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
21. Yu Z, Weinberger PM, Provost E, et al. β-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res 2005;11:2471-7.
22. Schulgen G, Lausen B, Olsen JH, Schumacher M. Outcome-oriented cutpoints in analysis of quantitative exposures. Am J Epidemiol 1994;140:172-84.
23. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics 1992;48:73-85.
24. 2 statistics. Biometrics 1982;38:1011-6.
25. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
26. Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-20.
27. Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999;59:3245-50.
28. 1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90-9.
29. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
30. Rahman A, Maitra A, Ashfaq R, Yeo CJ, Cameron JL, Hansel DE. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. Am J Clin Pathol 2003;120:685-90.
31. Watanabe J, Sato H, Kanai T, et al. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus-correlation with proliferation and clinicopathological parameters. Br J Cancer 2002;87:81-5.
32. Masciullo V, Ferrandina G, Pucci B, et al. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 2000;6:4816-22.
33. Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 1999;154:119-25.
34. Baekelandt M, Holm R, Trope CG, Nesland JM, Kristensen GB. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res 1999;5:2848-53.
35. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999;85:669-77.
36. Nycum LR, Smith LM, Farley JH, Kost ER, Method MW, Birrer MJ. The role of p27 in endometrial carcinoma. Gynecol Oncol 2001;81:242-6.
37. Kouvaraki M, Gorgoulis VG, Rassidakis GZ, et al. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors. Cancer 2002; 94:2454-65.
38. Cheng JD, Werness BA, Babb JS, Meropol NJ. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res 1999;5:1057-62.
39. Shoji M, Dobashi Y, Morinaga S, Jiang SX, Kameya T. Tumor extension and cell proliferation in adenocarcinomas of the lung. Am J Pathol 1999;154:909-18.
40. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997;94: 6380-5.
41. Barnouin K, Fredersdorf S, Eddaoudi A, et al. Anti-proliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Oncogene 1999;18:6388-97.
42. Cheng M, Olivier P, Diehl JA, et al. The p21 (Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571-83.